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Abstract
Background: Cytomegalovirus retinitis is a neglected disease in resource-poor settings, in part because of the
perceived complexity of care and because ophthalmologists are rarely accessible. In this paper, we describe a pilot
programme of CMV retinitis management by non-ophthalmologists. The programme consists of systematic
screening of all high-risk patients (CD4 <100 cells/mm
3) by AIDS clinicians using indirect ophthalmoscopy, and
treatment of all patients with active retinitis by intravitreal injection of ganciclovir. Prior to this programme, CMV
retinitis was not routinely examined for, or treated, in Myanmar.
Methods: This is a retrospective descriptive study. Between November 2006 and July 2009, 17 primary care AIDS
clinicians were trained in indirect ophthalmoscopy and diagnosis of CMV retinitis; eight were also trained in
intravitreal injection. Evaluation of training by a variety of methods documented high clinical competence.
Systematic screening of all high-risk patients (CD4 <100 cells/mm
3) was carried out at five separate AIDS clinics
throughout Myanmar.
Results: A total of 891 new patients (1782 eyes) were screened in the primary area (Yangon); the majority of
patients were male (64.3%), median age was 32 years, and median CD4 cell count was 38 cells/mm
3. CMV retinitis
was diagnosed in 24% (211/891) of these patients. Bilateral disease was present in 36% of patients. Patients with
active retinitis were treated with weekly intravitreal injection of ganciclovir, with patients typically receiving five to
seven injections per eye. A total of 1296 injections were administered.
Conclusions: A strategy of management of CMV retinitis at the primary care level is feasible in resource-poor
settings. With appropriate training and support, CMV retinitis can be diagnosed and treated by AIDS clinicians
(non-ophthalmologists), just like other major opportunistic infections.
Background
In south-east Asia, cytomegalovirus (CMV) retinitis is a
neglected disease [1], with no defined strategy for man-
agement [2,3]. This is despite evidence that CMV retinitis
is a common cause of HIV-associated blindness in this
region [4] and the second most common opportunistic
infection to emerge during initiation of antiretroviral
therapy (ART) [5], and that CMV viremia is a strong pre-
dictor of mortality [6].
The emerging body of data from resource-limited set-
tings closely mirrors what was learned several decades
ago in western countries about CMV infection in patients
with AIDS. At that time, about one-third of patients with
AIDS developed CMV retinitis, accounting for more than
90% of cases of HIV-related blindness [7,8]. Furthermore,
extra-ocular CMV disease was a major cause of AIDS-
related morbidity and mortality [9-11].
In resource-limited settings, the management of CMV
retinitis is inadequate. Primary care clinicians have been
reluctant to engage in the care of CMV retinitis, partly
because of inadequate training in diagnostic approaches
and partly because the most commonly available
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p r o c e d u r et h a to n l ya no p h t h almologist could perform
safely. But ophthalmologists are limited in number and
often distant from the need, based in urban secondary
or tertiary care facilities [12]. In addition, many ophthal-
mologists in developing countries may lack the skills or
equipment for adequate management of CMV retinitis.
The end result is that when patients are referred to
ophthalmologists they commonly arrive when the dis-
ease is at a late stage and outcomes are poor. Thus,
there is a need for a simple and effective system for
management of CMV retinitis that can be implemented
at the primary care level.
This unmet need was apparent in the Médecins Sans
Frontières (MSF) AIDS project in Myanmar, a country
with limited resources and the third highest prevalence of
HIV in south-east Asia (adult prevalence 0.67%). In Myan-
mar, about 240,000 persons are living with HIV/AIDS.
There are about 13,000 incident infections and 25,000
AIDS-related deaths each year [13,14]. Availability of ART
in Myanmar is limited, with only about one in four people
in need of ART receiving medication.
In this article, we report on a pilot programme for the
integration of management of CMV retinitis into routine
care for patients with HIV/AIDS at the primary care
level in Myanmar.
Methods
Programme setting
MSF provides HIV/AIDS services and ART to more than
15,000 persons in Myanmar through 15 clinics in Yangon
Division, Shan State, Kachin State and Rahkine State.
Services include health education, HIV screening, coun-
selling, treatment of opportunistic infections, nutritional
support and ART.
In November 2006, a screening programme for CMV
retinitis was initiated within the MSF HIV programme,
with training provided by a consultant ophthalmologist
to a national HIV/AIDS clinician with no prior ophthal-
mology training. This clinician then assumed responsi-
bility for programme supervision and development.
Selection of subsequent clinicians was primarily based
on the clinical needs in the different geographic loca-
tions in Myanmar where AIDS clinics are run by MSF.
Clinicians were qualified for selection if they had at least
one year of experience in the AIDS clinic, were inter-
ested in learning how to manage CMV retinitis, and
were judged by their supervisors to be highly motivated
and with a strong commitment to clinical care. All were
under 30 years of age. Formal training workshops were
started in 2007, and all 17 AIDS clinicians in this pro-
gramme had clinical training directly from a consultant
ophthalmologist in a workshop setting.
Screening and diagnosis
CMV screening was included as part of the protocol for
clinical evaluation of all consecutively enrolled new
patients in the ART programme from November 2006.
As the service became known, patients were referred
from private clinics, government hospitals, and non-
governmental organizations.
Screening consisted of examination of the entire retina
using an indirect ophthalmoscope (screening for ocular
symptoms was attempted in a similar setting and found
to be unreliable [1]). The pupil was fully dilated with
topical neosynephrine 2.5% and tropicamide 1%. The
diagnosis of CMV retinitis was based on clinical exami-
nation of the retina.
Screening criteria were broad, reflecting the principle
that examination of the retina should be part of the
basic physical examination of all AIDS patients at high
risk for opportunistic infections. Patients who met any
of the following criteria were screened: CD4 count
below 100 cells/mm
3; ocular symptoms consistent with
CMV retinitis (blurred vision, floaters, scotomata,
photopsia); symptoms consistent with extraocular CMV
such as unexplained diarrhoea or dysphagia; symptoms
of meningitis (fever, headache, altered mental status);
herpes zoster ophthalmicus; and suspicion of dissemi-
nated tuberculosis. Patients with cotton-wool spots at
the first screening visit were re-examined every three
weeks until the spots resolved. Patients with normal
retinas at the first screening visit were re-screened every
t h r e em o n t h sa sl o n ga st h e i rC D 4c o u n t sr e m a i n e d
under 100 cells/mm
3.
Treatment
Patients diagnosed with active CMV retinitis were treated
on the same day with intraocular ganciclovir (2.5 mg gan-
ciclovir in 0.05mL of solution) followed by weekly injec-
tions for as long as clinically required. Injections were
administered in the AIDS clinic by standard procedure,
using an eyelid speculum, betadine preparation, and sterile
no-touch technique. If patients were not yet on ART,
plans were made to initiate ART, if possible about two
weeks after the first ganciclovir injection. Patients already
on ART with immune reconstitution and inactive CMV
retinitis were observed. Most of these patients had been
treated with ART for four to six months and were referred
from other programmes with visual complaints.
Training approach
A training workshop for the diagnosis and treatment of
CMV retinitis was developed and refined in Myanmar
over three years. The curriculum focused narrowly on
teaching indirect ophthalmoscopy and management of
CMV retinitis. The training was task oriented: trainees
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retinitis in order to make the clinical decision to either
start or discontinue CMV treatment.
The training workshop was four days long and
included short didactic lectures on relevant ocular anat-
omy, CMV retinitis and other HIV/AIDS-related retinal
pathology, as well as training in indirect ophthalmo-
scopy using model eyes. This was followed by case-
based teaching using patients with AIDS-related eye dis-
ease. The AIDS clinicians were taught how to perform
rapid bedside screening for blindness and visual field
loss and palpation for low intraocular pressure second-
ary to retinal detachment. AIDS clinicians working in
locations where intraocular injection skills were other-
wise not available were carefully trained in intraocular
injection of ganciclovir (intravenous ganciclovir and oral
valganciclovir are not available in Myanmar). Through-
out the workshop, there were case-based drills using
photographic clinical material.
The goal of this curriculum was specifically to train
AIDS clinicians to manage CMV retinitis, not to develop
“primary eye care providers”. No attempt was made to
present a systematic primary eye care curriculum.
Evaluation of training
At the end of the first workshop, the ability of five AIDS
physicians to diagnose active and inactive CMV retinitis
by indirect ophthalmoscopy was assessed by Kappa sta-
tistics. Thirty patients (60 eyes) were examined after
appropriate consents were obtained. Examination of
these patients by a consultant ophthalmologist (DH)
served as the gold standard. For statistical analysis, only
the right eye was used.
Training has also been consistently evaluated by a
variety of informal methods that will be described.
Ethics
The programme evaluation was based on routine clinical
data, therefore ethical review and individual patient con-
sent were not sought. All patient information was
entered into a database using coded identification num-
bers, and no information that could reveal patient iden-
tity was collected.
Results
Between November 2006 and July 2009, 891 new patients
were screened for CMV retinitis in the Yangon Division
(Table 1). The most common reason for screening was
CD4 cell count <100 cells/mm
3. The majority of patients
were male (64.3%), the median age was 32 years, and the
median CD4 cell count was 38 cells/mm
3.
CMV retinitis was diagnosed in 211 of 891 (24%) new
patients in Yangon Division, with bilateral disease in 76
of 211 (36%) patients. Of 1782 eyes screened, 287 (16%)
were diagnosed with CMV retinitis (Table 2). CMV
screening declined in 2008 and 2009, mainly due to pro-
gramme resource constraints. For Shan State, Kachin
State and Rahkine State, data is incomplete except for
the information that an additional 268 patients were
screened in Shan State and 292 in Kachin State.
The five physicians who participated in the first work-
shop were assessed with a Kappa agreement analysis for
their ability to diagnose active and inactive CMV retinitis
with the indirect ophthalmoscope. With 30 patients, the
retina of two eyes could not be examined due to catar-
acts. Of the remaining 58 eyes, 29 had no disease, 23 had
active CMV retinitis, and 15 had retinal scars consistent
with inactive CMV retinitis (in addition, six eyes had ret-
inal detachment, three eyes had cotton-wool spots, and
six had choroidal granulomas characteristic of tuberculo-
sis). One of the clinicians (NNT) had been instructed by
the consultant ophthalmologist the previous year and
already had one year of clinical experience.
The Kappa statistic for the clinician with one year
experience was 1.0 (perfect agreement) for recognizing
both active and inactive CMV retinitis. The strength of
agreement (Kappa statistic) for the four other AIDS clini-
cians taking the workshop for the first time ranged from
0.73 to 0.51 (average of 0.64 or “substantial” agreement)
for the diagnosis of active CMV retinitis, and 0.72 to 0.39
(average of 0.55 or “moderate” agreement) for the recog-
nition of inactive CMV retinitis.
Workshop performance was also evaluated with tests
using photographic images of retinal lesions from AIDS
patients. In tests given on the final day of the three work-
shops during the period covered in this report, the average
score of the 17 AIDS clinicians was 94%. Self-evaluations
carried out on the final morning of each workshop consis-
tently reported a high level of confidence about the ability
to examine the eye with the indirect ophthalmoscope, a
high level of confidence in recognizing the key retinal
landmarks, and a moderate to high confidence in making
the diagnosis of active and inactive CMV retinitis. The
results of self-evaluation were consistent with the impres-
sion of the workshop instructor who, at the time of patient
examinations, reviewed all of the retinal drawings pro-
duced by each of the AIDS clinicians as part of their work-
shop training.
By July 2009, 17 AIDS clinicians had been trained in
the diagnosis of CMV retinitis by indirect ophthalmo-
scopy, eight had been trained in the intraocular injection
of ganciclovir, and 1296 intraocular injections of ganci-
clovir already had been performed. Thirty-four injections
were directly observed by the consultant ophthalmologist
(DH). In the course of 1296 intraocular injections, there
was a single case of infectious endophthalmitis. Minor
complications (such as subconjunctival hemorrhage)
were not recorded. There have been no significant
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ophthalmic setting (no attacks of angle-closure
glaucoma).
Four AIDS clinicians were re-evaluated one year after
training. In side-by-side examination of patients who
had been treated with intraocular injection for CMV
retinitis by the AIDS clinicians, consultant ophthalmolo-
gists (DH, NL) confirmed the correct diagnosis of CMV
retinitis in 213 of 218 eyes (98%) or 161 of 166 patients
(97%). The five incorrect diagnoses were syphilis (n =
1), myelinated nerve fibre layer (n = 1), tuberculosis
(n = 2), and ocular toxoplasmosis (n = 1).
Discussion
This report documents the feasibility of training primary
care AIDS clinicians to diagnose and treat CMV retinitis
in a resource-limited setting. CMV retinitis screening is
now carried out in four regions in Myanmar, and at the
beginning of 2010, covered the majority of patients trea-
ted with ART in the country.
The high prevalence of CMV retinitis that we identified
and the severity of the consequences of CMV retinitis
demonstrate the importance of routine CMV retinitis
screening in this setting. CMV retinitis was diagnosed in
211 out of 891 (24%) new patients screened in the Yangon
Division, and these patients required urgent treatment to
prevent blindness. Blindness has catastrophic conse-
quences for these patients who are at a relatively young
age, as well as for their families.
We are aware of the potential risk of causing an attack
of acute angle-closure glaucoma and blindness by
dilation of the pupil in a setting where back-up ophthal-
m i cc a r em a yn o tb ea v a i l a b l e .H o w e v e r ,w ec o n s i d e r
that overall, the balance of risks finds in favour of using
this approach: while the risk of angle closure is low (no
episodes thus far), the risk of blindness from undetected
and untreated CMV retinitis in this population is high.
Our experience in Myanmar demonstrates the feasibil-
ity of training AIDS clinicians to diagnose and treat
CMV retinitis. Even with a limited background in
ophthalmology, CMV retinitis is not difficult to diag-
n o s e .A tt h ee n do ft h ef o u r - d a yw o r k s h o p ,m o s tA I D S
clinicians were able to begin screening patients with the
indirect ophthalmoscope, and after three to six months
of practice, most were highly proficient. By one year,
AIDS clinicians regarded CMV retinitis as the easiest
diagnosis to establish among major opportunistic infec-
tions whereas previously, it was regarded as the most
difficult. However, diagnosis of the ophthalmologic com-
plications of CMV retinitis, retinal detachment and
immune recovery uveitis (IRU) remains a challenge, as
does distinguishing active from inactive retinitis in
patients with IRU.
This report comes from a routine programme and as
such there are several potential limitations to note. It is
p o s s i b l et h a ts o m ec l i n i c a le v e n t sw e r em i s s e dd u et o
missed appointments or unrecorded events. We are con-
fident that the recording of important clinical events is
reliable given that a strong emphasis is placed on data
collection to support cohort monitoring in this pro-
gramme. As is the case for HIV/AIDS care generally in
many settings in the developing world, this programme
Table 1 Baseline characteristics of patients screened for CMV retinitis in Yangon
2006* 2007 2008 2009** Total
Number of new patients screened 55 598 164 74 891
Number of follow-up examinations 101 496 431 262 1290
% female
† 38.5% 32.3% 41.7% 38.5% 35.7%
Median age (years)
† 30 32 32 33 32
Median CD4 (IQR) 32 (16-56) 36 (20-60) 44 (25-87) 41 (21-65) 38 (21-66)
† 3% missing data.
* Data collection started November 2006.
** Includes data until June 2009.
Table 2 Diagnosis following screening for CMV retinitis in Yangon (by eyes)
2006* 2007 2008 2009** Total
Active CMVR 29 (26%) 93 (8%) 40 (15%) 44 (30%) 216 (12%)
Inactive CMVR 10 (9%) 17 (1%) 26 (8%) 18 (12%) 71 (4%)
No CMV 69 (63%) 1083 (91%) 232 (71%) 14 (9%) 1398 (78%)
Missing data or other 2 (2%) 3 (0.3%) 20 (6%) 72 (49%) 97 (5%)
Total 110 (100%) 1196 (100%) 328 (100%) 148 (100%) 1782 (100%)
* Data collection started November 2006.
** Includes data until June 2009.
Percentages may not add up to exactly 100% due to rounding.
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that provides additional resources that may limit the
potential for replication in settings where such addi-
tional resources are lacking. However, we consider that
with adequate commitment, training and support, the
approach could be extended to other, similar settings.
The set-up cost for a CMV retinitis screening pro-
gramme is modest: the only equipment needed is a porta-
ble battery-operated indirect ophthalmoscope with a 28
diopter lens. Dilating drops are inexpensive. Only one clin-
ician needs to be trained per centre, and that clinician car-
ries out all the screening and patient management so as to
remain highly practiced and skilled. Screening of one
patient (two eyes) takes approximately three minutes, and
one intraocular injection takes 15-20 minutes. In Myan-
mar, diagnostic screening and treatment has usually been
managed within a single half-day clinic each week.
Treatment, however, remains problematic. As we found,
treatment with intraocular injection of ganciclovir can
safely be implemented at the primary care level by non-
ophthalmologists, and we strongly support this treatment
intervention in the absence of alternatives. Ganciclovir
injection is certainly affordable [1], costing less than US
$1.00 per weekly injection, and intraocular injection of
ganciclovir is highly effective at controlling retinitis in the
injected eye. However, intraocular injection does not treat
or prevent against potentially fatal extra-ocular CMV dis-
ease, nor does it prevent the development of disease in the
contralateral eye. It requires weekly clinic visits that may
be cumbersome, and patients must endure repeated injec-
tions into the eye.
In contrast, patients in developed countries are treated
for the same problem with a simple pill. Systemic treat-
ment of CMV retinitis with oral valganciclovir is the
standard of care in western countries [14,15]. Reduction
in mortality has been observed with systemic treatment
of CMV retinitis [16], even in patients failing ART ther-
a p y[ 1 7 ] .A l t h o u g hw ea r en o ta b l et op r o v i d eo u t c o m e
data in support for this standard of care in this report, we
consider that that available evidence supports the use of
intraocular injection as a valuable step in providing high-
quality care to patients with CMV retinitis. However,
intraocular injection alone is not adequate. Systemic
treatment with oral valganciclovir [18] should be made
affordable and widely available.
Future research should more adequately document the
prevalence of CMV in resource-limited settings, and
better evaluate treatment outcomes for patients treated
with valganciclovir and intraocular ganciclovir, including
through randomized trials.
Conclusions
CMV retinitis, one of the major opportunistic infections
of HIV/AIDS, will remain a clinical problem and cause
of avoidable mortality and blindness until there is wide-
spread early detection of HIV infection and early initia-
tion of antiretroviral therapy at higher CD4 counts.
Until that time, we believe that management of CMV
retinitis needs to be integrated into routine care for
patients with HIV/AIDS at the primary care level in
Mynamar and similar settings, as is the done with other
important opportunistic infections. Simple and effective
management of CMV retinitis in resource-poor settings
is a realistic goal. We recommend that other HIV/AIDS
programmes in south-east Asia managing patients at
potential risk of CMV retinitis move forward with simi-
lar initiatives.
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